Sorafenib and Temozolomide in Treating Patients With Stage III or Stage IV Melanoma
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy,
such as temozolomide, work in different ways to stop the growth of tumor cells, either by
killing the cells or by stopping them from dividing. Giving sorafenib together with
temozolomide may kill more tumor cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of giving sorafenib
together with temozolomide in treating patients with stage III or stage IV melanoma.